Biologics

The era of one-size-fits-all medicine is ending. Healthcare is undergoing a profound transformation where treatments are no longer prescribed based on average patient responses but tailored to individual genetic blueprints. Artificial intelligence has emerged as the catalyst driving this revolution, processing vast genomic datasets to unlock personalised treatment possibilities previously confined to science fiction. From […]

India stands at the cusp of an industrial revolution, powered by strategic government initiatives that promise to reshape its economic landscape. The BioE3 Policy and Production Linked Incentive (PLI) schemes represent more than mere policy frameworks—they embody India’s ambition to emerge as a global powerhouse in biotechnology and manufacturing. With substantial investments flowing into critical

For centuries, medicine operated on a brutal assumption: what cures one person should cure another with the same diagnosis. This one-size-fits-all approach saved countless lives, yet left equally countless patients suffering through ineffective treatments or devastating side effects because their bodies simply processed drugs differently. India is now dismantling this paradigm through precision medicine—an approach

India’s pharmaceutical regulatory system faces an uncomfortable truth—the framework that served generic drugs brilliantly for decades is increasingly obsolete. The present structure, developed primarily for chemical generics, struggles mightily to regulate biologics, cell therapy, and cutting-edge advanced medicines requiring specialised standards. Industry experts warn that generics are becoming yesterday’s business as the global pharmaceutical market

India’s pharmaceutical industry is simultaneously pursuing two revolutionary paths that seem unrelated but share a common thread—saving lives more ethically and effectively. The country recently eliminated mandatory animal testing for drug development whilst simultaneously ramping up efforts against antimicrobial resistance that threatens to kill 10 million people annually by 2050. These aren’t minor policy adjustments

India’s biotechnology sector buzzes with potential, yet a frustrating disconnect persists between government promises and ground realities. Whilst the Department of Biotechnology launches ambitious schemes worth thousands of crores, startup founders in Bengaluru and Hyderabad tell different stories. They speak of delayed funding, bureaucratic labyrinths, and support that sounds impressive on paper but rarely materialises